Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma

INTRODUCTION: Idarucizumab is the first effective humanized monoclonal antibody fragment developed specifically as a reversal agent for dabigatran, a Direct Oral Anticoagulant. Despite recent trials demonstrating reversal of clinically relevant bleeding, there is a paucity of data on use outside the...

Descripción completa

Detalles Bibliográficos
Autores principales: Edwards, Gail, Roman, Cristina, Jithoo, Rondhir, Mitra, Biswadev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887121/
https://www.ncbi.nlm.nih.gov/pubmed/29644298
http://dx.doi.org/10.1016/j.tcr.2017.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887121/
https://www.ncbi.nlm.nih.gov/pubmed/29644298
http://dx.doi.org/10.1016/j.tcr.2017.12.003

Ejemplares similares